Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule

Jul 16 2018

• By Mandy Jackson

Finance Watch

Related Content

Another Early-Stage VC Win: Pliant Raises $45m For Fibrosis Startup

Feb 18 2016

Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches

Nov 10 2017

What's Next For Roivant? It's Not More Publicly Traded "Vants"

Jul 13 2017

Wellcome Trust Seeks 'Talent Scout' CEO For New Fund For Risky Health Ideas

Jul 11 2018

Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend

Feb 05 2018

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

Apr 18 2018

Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks

May 22 2018

Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight

Jun 27 2018

Forbion Sees First Close Of New Biotech Fund At €270M In Record Time

Jul 10 2018

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Jul 11 2018

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Jun 27 2017

Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics

Aug 02 2017

Related Companies

Crinetics Pharmaceuticals, Inc.

Allakos Inc.

Constellation Pharmaceuticals, Inc.

Rubius Therapeutics, Inc.

Replimune Group Inc.

Roivant Sciences Ltd.

Urovant Sciences, Inc.

Merck & Co., Inc.

Moderna, Inc.

Pliant Therapeutics, Inc.

Nohla Therapeutics, Inc.

Antiva Biosciences, Inc.

Antabio SAS

Additional Topics

Financing Business Strategies StartUps and SMEs Commercial BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window